SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.85-4.5%Jan 9 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (9114)9/11/2003 5:54:32 PM
From: Michael Young  Read Replies (1) of 52153
 
I find it sad that so many investors blame the shorts or street.com columnists when they simply are pointing out the games bio managements tend to play. Very, very rarely does the FDA approve drugs when primary end points are not met. Heck, even with ITMN we were simply hoping the Phase III data would increase off label sales. We knew actual FDA approval for the IPF indication was a long shot.

But companies like Genta will continue to put lipstick on pigs and blame the FDA when the drugs are rejected.

MIKE
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News